Perspectives of the Application of Liquid Biopsy in Colorectal Cancer

Ding, Yuhan; Li, Wenxia; Wang, Kun; Xu, Chang; Hao, Mengdi; Ding, Lei

doi:10.1155/2020/6843180

Cited by 43 publications

(47 citation statements)

References 143 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Second, there is a lack of standard procedures for the sample preparation or the pre-analytical phase for liquid biopsy, resulting in difficulties to compare obtained results across different methodology approaches [ 142 , 143 , 144 , 145 ]. Third, the diagnostic accuracy and sensitivity of current available liquid biopsy assays are limited [ 99 , 146 ]. Fourth, sophisticated multicenter clinical validation studies and regulatory guidelines are lacking but must be established to ensure future clinical utility [ 147 ].…”

Section: Challenges and Future Directionsmentioning

confidence: 99%

Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker

et al. 2021

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most commonly-diagnosed cancer in the world and ranked second for cancer-related mortality in humans. Microsatellite instability (MSI) is an indicator for Lynch syndrome (LS), an inherited cancer predisposition, and a prognostic marker which predicts the response to immunotherapy. A recent trend in immunotherapy has transformed cancer treatment to provide medical alternatives that have not existed before. It is believed that MSI-high (MSI-H) CRC patients would benefit from immunotherapy due to their increased immune infiltration and higher neo-antigenic loads. MSI testing such as immunohistochemistry (IHC) and PCR MSI assay has historically been a tissue-based procedure that involves the testing of adequate tissue with a high concentration of cancer cells, in addition to the requirement for paired normal tissues. The invasive nature and specific prerequisite of such tests might hinder its application when surgery is not an option or when the tissues are insufficient. The application of next-generation sequencing, which is highly sensitive, in combination with liquid biopsy, therefore, presents an interesting possibility worth exploring. This review aimed to discuss the current body of evidence supporting the potential of liquid biopsy as a tool for MSI testing in CRC.

show abstract

Section: Challenges and Future Directionsmentioning

confidence: 99%

Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker

et al. 2021

View full text Add to dashboard Cite

show abstract

“…CTCs have been investigated in colorectal cancer with different approaches, based on both physical properties of CTCs or marker expression [116]. From a clinical point of view, CTCs have been explored as biomarkers for screening, auxiliary staging of colorectal cancer, prognosis, monitoring drug resistance, and guiding medication as well as monitoring tools for minimal residual disease (MRD) [117]. Some studies explored the possibility of using CTC detection for the screening of colorectal cancer with encouraging results, but the sensitivity of the currently available techniques for CTC identification is still insufficient for enabling early diagnosis, since CTCs are infrequent in early stages of disease [118,119].…”

Section: Colorectal Cancermentioning

confidence: 99%

Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors

Pinzani

D’Argenio

et al. 2021

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

Despite advances in screening and therapeutics cancer continues to be one of the major causes of morbidity and mortality worldwide. The molecular profile of tumor is routinely assessed by surgical or bioptic samples, however, genotyping of tissue has inherent limitations: it represents a single snapshot in time and it is subjected to spatial selection bias owing to tumor heterogeneity. Liquid biopsy has emerged as a novel, non-invasive opportunity of detecting and monitoring cancer in several body fluids instead of tumor tissue. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), RNA (mRNA and microRNA), microvesicles, including exosomes and tumor “educated platelets” were recently identified as a source of genomic information in cancer patients which could reflect all subclones present in primary and metastatic lesions allowing sequential monitoring of disease evolution. In this review, we summarize the currently available information concerning liquid biopsy in breast cancer, colon cancer, lung cancer and melanoma. These promising issues still need to be standardized and harmonized across laboratories, before fully adopting liquid biopsy approaches into clinical practice.

show abstract

“…Assessment of peripheral blood components, such as CTCs, ctDNA, miRNAs, and lncRNAs could improve CRC screening and diagnosis, and predict relapse and metastasis [ 19 , 20 , 21 , 22 ]. Blood-based liquid biopsies could also be effective in monitoring minimal residual disease (MRD) and drug resistance in CRC patients receiving chemotherapy [ 23 , 24 ] ( Table 1 ).…”

Section: Clinical Utility Of Liquid Biopsies In Patients With Colomentioning

confidence: 99%

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

et al. 2020

View full text Add to dashboard Cite

Currently, there is a crucial need for novel diagnostic and prognostic biomarkers with high specificity and sensitivity in patients with colorectal cancer. A “liquid biopsy” is characterized by the isolation of cancer-derived components, such as circulating tumor cells, circulating tumor DNA, microRNAs, long non-coding RNAs, and proteins, from peripheral blood or other body fluids and their genomic or proteomic assessment. The liquid biopsy is a minimally invasive and repeatable technique that could play a significant role in screening and diagnosis, and predict relapse and metastasis, as well as monitoring minimal residual disease and chemotherapy resistance in colorectal cancer patients. However, there are still some practical issues that need to be addressed before liquid biopsy can be widely used in clinical practice. Potential challenges may include low amounts of circulating tumor cells and circulating tumor DNA in samples, lack of pre-analytical and analytical consensus, clinical validation, and regulatory endorsement. The aim of this review was to summarize the current knowledge of the role of liquid biopsy in the management of colorectal cancer.

show abstract

Perspectives of the Application of Liquid Biopsy in Colorectal Cancer

Cited by 43 publications

References 143 publications

Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker

Microsatellite Instability in Colorectal Cancer Liquid Biopsy—Current Updates on Its Potential in Non-Invasive Detection, Prognosis and as a Predictive Marker

Updates on liquid biopsy: current trends and future perspectives for clinical application in solid tumors

The Liquid Biopsy in the Management of Colorectal Cancer: An Overview

Contact Info

Product

Resources

About